Navigation Links
Coming Soon: Lung-Cancer Spray?
Date:6/15/2009

Novel delivery of gene therapy suppresses tumors in mice

MONDAY, June 15 (HealthDay News) -- Scientists may someday be able to fight lung cancer using gene therapy delivered by an inhalable spray.

In a new study, mice with lung cancer that were treated with a vaporized viral vector twice a week for four weeks had fewer, smaller tumors than untreated mice.

Researchers also found that treated mice had increased apoptosis, or programmed cell death, necessary for healthy tissues, as well as suppressed production of several proteins that contribute to cancer cell growth.

The study, by researchers at Seoul National University in Korea, appears in the June 15 issue of the American Journal of Respiratory and Critical Care Medicine.

"Aerosol delivery targets the lungs specifically and represents a noninvasive alternative for targeting genes to the lung," wrote study author Myung-Haing Cho, a professor at Seoul National University. "The delivery of genes via aerosol holds promise for the treatment of a broad spectrum of pulmonary disorders and offers numerous advantages over more invasive modes of delivery."

In the study, researchers used a lentiviral vector derived from a retrovirus able to infect non-dividing cells, causing lasting genetic changes. The lentiviral vector included a carboxyl-terminal modulator protein (CTMP), which inhibits Akt signaling.

Previous research has shown 90 percent of non-small cell lung carcinomas involve the Akt signaling pathway, according to the study.

Researchers divided mice into three groups: one received the aerosolized CTMP vector, one received the vector alone and one third were untreated.

The mice treated by the CTMP vector had significantly fewer, smaller tumors.

Globally, lung cancer is the most common cause of cancer deaths. Most treatments, including surgery, radiation and chemotherapy, slow progression of the disease only temporarily.

While much research is underway on the use of gene therapy to treat lung cancer, one stumbling block has been finding delivery mechanisms that work.

"Our results demonstrated that lentivirus-mediated CTMP overexpression suppressed Akt activity and inhibited tumor progression," Cho wrote.

More information

The National Cancer Institute has more on lung cancer.



-- Jennifer Thomas



SOURCE: American Journal of Respiratory and Critical Care Medicine, news release, June 15, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Digital TV Transition Coming Soon; Update Preparedness Plans
2. Kendle to Present at Upcoming Jefferies and Wachovia Securities Conferences
3. Align Technology Executive to Present at Upcoming Financial Conference
4. Upcoming Investor Events at The American Association for Clinical Chemistry (AACC) Annual Meeting & Clinical Lab Exposition
5. Almost Family to Present at Two Upcoming Conferences
6. B. Braun Anticipates Becoming First to Deliver FDA Approved 2g Cefazolin
7. drugstore.com, inc. to Present at Upcoming Financial Conferences
8. WellPoint Announces Appearances at Upcoming Conferences
9. ResMed Inc. to Present at Upcoming Conferences in June
10. Finding a New Doctor Becoming More Difficult for Medicare Recipients Says MedicareSupplementPlans.com
11. Medivation Announces Upcoming Presentation of New MDV3100 Data in Patients With Advanced Prostate Cancer at 45th American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Coming Soon:  Lung-Cancer Spray?
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... ... 24, 2016 , ... EB Medicine presented its first-ever “Issue ... conference in Ponte Vedra Beach, FL. The awards honor the outstanding work of ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/23/2016)...  MedSource announced today that it has selected ... of choice.  This latest decision demonstrates MedSource,s commitment ... clients by offering a state-of-the-art electronic data capture ... as the EDC platform of choice in exchange ... has long been a preferred EDC platform by ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: